2023 is shaping up to be a pivotal year for Aldeyra Therapeutics Inc. (ALDX) as it continues to make significant progress in its pipeline of compounds targeting systemic and retinal immune-mediated diseases.
Two of the company's drug candidates - ADX-2191 and Reproxalap - are under FDA review.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com